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Objective: To investigate whether tumor necrosis factor-a (TNFa) -238G/A and -308G/
A polymorphisms are associated with susceptibility to pulmonary tuberculosis (TB) in the
Lur ethnic population of Iran.
Methods: TNF polymorphisms genotyping was performed by polymerase chain
reaction-restriction fragment length polymorphism method in 100 pulmonary TB patients
and 100 healthy controls from the Lur population.
Results: The allelic and genotypic frequencies of TNFa -238G/A polymorphism were
not signiﬁcantly different between the pulmonary TB patients and the healthy controls.
However, the TNFa -308G/A polymorphism showed a signiﬁcantly higher frequency of
genotype GG in TB subjects compared to healthy controls (94% in the patients vs. 62% in
the controls, P = 0.0001, odds ratio = 0.104, conﬁdence interval = 0.028–0.382).
Moreover, in the TNFa -308G/A polymorphism, a signiﬁcantly higher frequency of G
allele was measured in the patient group compared with the control group (97% in the
patient group vs. 81% in the control group, P = 0.0001, odds ratio = 0.132, conﬁdence
interval = 0.038–0.462).
Conclusions: Our ﬁndings suggest that TNFa -308G/A polymorphism may increase the
susceptibility to pulmonary TB in the Lur population of Iran. Despite TNFa poly-
morphisms and susceptibility to pulmonary TB, we suggest that more studies with larger
sample size are needed in the future. Increasing our understanding of susceptibility risk
factors may help to improve current preventive measures and treatment for TB.1. Introduction
Tuberculosis (TB) is caused by the acid fast bacillus,
Mycobacterium tuberculosis (MTB). TB is a common infectious
disease. Worldwide, there are 9 million novel cases and 2
million mortalities annually [1]. It has been suggested that
sensitivity to this disease is variable in the different
populations and that contact with this microorganism does not
always result in infection. Almost one third of the world
population is infected by this bacterium of which 5%–10% areinfected with the active form of TB. Additionally, the course
and duration of disease vary in different individuals [2].
These differences may be due to host factors and genetic
sensitivity of different individuals to this disease [3,4]. Different
genetic factors are implicated in the susceptibility to and severity
of TB, one of which is KIR3DS1 gene and it combines with
HLA-B Bw4 and Ile80 ligand [5]. Moreover, human and mouse
studies on MTB infection have demonstrated different loci in the
susceptibility or resistance to TB such as toll like receptors [6–10].
It has been reported that tumor necrosis factor (TNF) is involved
in the prevention of mycobacterial infection development and
also in preventing progression from latent to active TB form [11–14].
TNFa is a cytokine involved in the innate immunity. It is
primarily formed against pathogens, and its genetic poly-
morphisms play an important role in the immune response ef-
ﬁcacy against major infections. The principal source of TNFa
production is the mononuclear phagocytes. The release of TNFan open access article under the CC BY-NC-ND
Table 2
Distribution of TNF-a genotypes in TB patients group and healthy
controls group.
TNF-a
polymorphisms
Genotypes Associated
phenotypes
% of
TB patients
group
% of Healthy
controls
group
TNF (-238G/A) GG 96 92
GA 4 8
AA – –
TNF (-308G/A) GG Low 94* 62
GA Intermediate 6 38
AA High – –
*: Signiﬁcant difference (P < 0.05), n = 100.
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monocytes to the site of infection [15].
The effect of TNFa on the human body varies from activation of
inﬂammatory processes to activation of hepatocytes and tissue
damagebasedon its low,moderate andhighdoses. It also contributes
to activation of macrophages and regulates interferong production
[16]. Therefore, it initiates pro-inﬂammatory reactions implicated in
the effect on disease and resistance to theMycobacterium [17].
The human and animal TB investigations suggest that TNFa
impresses the innate immune response to TB [18]. Hence, TNFa
-238G/A and -308G/A polymorphisms have been analyzed
widely as the nominated genes for susceptibility to TB in
different populations [19–23]. Due to the differences between
distribution of TNFa gene in different races and nations and
also due to association of TNFa polymorphisms with
pulmonary TB susceptibility, we were interested to investigate
the prevalence of these polymorphisms in pulmonary TB
patients and healthy controls of the Lur population dwelled in
Lorestan Province. Therefore, the susceptibility to pulmonary
TB infection was ascertained by the studying of TNFa -238G/
A and -308G/A polymorphisms in the TB group and the
results were compared with the healthy control group.
2. Materials and methods
2.1. Patients and controls
This study was approved by the Ethics Committee of Lore-
stan University of Medical Sciences. All subjects gave informed
written consent. We used case control study to implement this
investigation. The patient group was comprised of 100 unrelated
Lur individuals referred to the health center of Khorramabad city
of Lorestan Province, with TB conﬁrmed by sputum culture. All
patients received TB standard treatment and none of them had
drug resistance. The control group was comprised of 100 un-
related Iranian individuals of the same race and geographic re-
gion. The controls were asymptomatic, had normal radiologic
results and their puriﬁed protein derivatives test was negative.
The control group was matched on age and sex with the patient
group. Additionally, all study subjects had parents of the same
race. The blood samples were collected for analysis.
2.2. Genotyping
Patient and control DNA samples were extracted using
QIAmp kit (Qiagen, Germany). The polymerase chain reaction-
restriction fragment length polymorphism previously suggested
by Fan et al. was performed to determine TNFa -238G/A and
-308G/A polymorphisms in patients and controls using their
genomic DNA [24]. The list of forward and reverse primerTable 1
Primer sequences, restriction enzymes used and restriction digestion patterns
TNF-a polymorphisms Sequences of the primers
TNF (-238G/A) F: 50 AGAAGACCCCCCTCGGAACC 30
R: 50 ATCTGGAGGAAGCGG TAGTG 30
TNF (-308G/A) F: 50 AGGCAATAGGTTTTGAGGGCCAT
R: 50 ACACTCCCCATCCTCCCT GCT 30
F: Forward; R: Reverse; bp: Base pairs.sequences (Qiagen, Germany), restriction enzymes (Biolabs,
USA) and digestion patterns for different alleles were assorted
in Table 1.
The ampliﬁcation was carried out by using Mastercycler
(BioRad, USA) in 20 mL reaction. Ampliﬁcation conditions used
were as follows: denaturation initiated at 94 C for 5 min and
was followed by 5 cycles of denaturation at 94 C for 5 min,
annealing at 60 C for 1 min, extension at 72 C for 1 min, and
25 cycles of denaturation at 94 C for 30 s, annealing at 60 C
for 30 s, extension at 72 C for 40 s with ﬁnal extension at 72 C
for 1 min. The PCR products were incubated with restriction
enzymes Msp I and Nco I at 37 C for TNFa -238G/A and
-308G/A, respectively for 24 h to digest the DNA. The elec-
trophoresis of PCR products was accomplished on 3% agarose
gel consisting of 0.5 mg/mL ethidium bromide. Finally, the
products were visualized by using an ultraviolet light.
2.3. Statistical analysis
The genotypic and allelic frequencies of TNFa -238G/A and
-308G/A polymorphisms were ascertained by direct counting in
the TB population and healthy control population. All poly-
morphisms were consistent with values predicted by Hardy–
Weinberg equilibrium in both patient and control groups. The
differences in the genotypic and allelic frequencies of TNFa
-238G/A and -308G/A polymorphisms were determined by the
Chi-squared test and Fisher's exact test between TB population
and healthy control population. Overall, P < 0.05 was consid-
ered statistically signiﬁcant after correction. The odds ratio (OR)
was calculated by the cross-product ratio and exact conﬁdence
interval (CI) of 95% was obtained.
3. Results
The study subjects comprised of 100 healthy controls with
the mean age, (30.21 ± 2.55) years and 100 pulmonary TBfor genotyping of TNF-a polymorphisms.
PCR product
size
Restriction
enzymes
Length of the
restriction fragments
for different alleles
152 bp Msp I G-133 bp + 19 bp
A-152 bp
30 117 bp Nco I G-97 bp + 20 bp
A-117 bp
Table 3
Distribution of TNF-a alleles in TB patients group and healthy controls
group.
TNF-a
polymorphisms
Alleles % Allele
frequency in TB
patients group
% Allele
frequency in healthy
controls group
TNF (-238G/A) G 98 96
A 2 4
TNF (-308G/A) G 97* 81
A 3 19
*: Signiﬁcant difference (P < 0.05).
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healthy controls, 50 individuals were males and 50 individuals
were females, and among the pulmonary TB patients, 40 in-
dividuals were males and 60 individuals were females.
The genotypic and allelic frequencies of TNFa -238G/A and
-308G/A polymorphisms were listed in Tables 2 and 3. The
genotypic and allelic frequencies of TNFa -238G/A poly-
morphism did not have signiﬁcant difference between the pul-
monary TB patients and the healthy controls. Also, AA
genotype of TNFa -238G/A polymorphism was not detected in
the patient and control groups. Only, in TNFa -308G/A poly-
morphism, a signiﬁcantly increased frequency of genotype GG
was observed among patients compared with controls (94% in
the patient group vs. 62% in the control group, P = 0.0001,
OR = 0.104, CI = 0.028–0.382). Also AA genotype of TNFa
-308G/A polymorphism was not observed in the patient and
control group (Table 2).
In the TNFa -308G/A polymorphism, a signiﬁcantly
increased frequency of G allele was observed among the patient
group compared with the control group (97% in the patient
group vs. 81% in the control group, P = 0.0001, OR = 0.132,
CI = 0.038–0.462) (Table 3).
4. Discussion
TNFa is one of the most signiﬁcant cytokines involving in
the primary host innate immunity against a pathogen. Moreover,
it is shown that TNFa is characteristic in the prevention of
mycobacterial establishment and preservation of TB in latent
form [11–14]. Among this, TNFa -238G/A and -308G/A
polymorphisms were widely determined as the nomination
genes in the susceptibility to TB infection [19–23].
In this study, we showed the effect of TNFa -238G/A and
-308G/A in the susceptibility to pulmonary TB in the Lur popu-
lation of Iran. The genotypic and allelic frequencies of TNFa
-308G/A polymorphism have signiﬁcant difference between pa-
tients infected by pulmonary TB and the healthy control in-
dividuals. The TNFa -238G/A polymorphism had no signiﬁcant
difference between pulmonary TB patients and the healthy control
group. In contrast, in the late studies carried out by Sharma et al.
[12] and Kumar et al. [21] in the north of India, there were no
association between these polymorphisms and pulmonary TB.
This phenomenon is not surprising because of genetic
nonidentity between Asians and Indians (racial differences).
Our results showed similar outcome as former studies in this
ﬁeld conducted by Fan et al. [24] and Qu et al. [25] on the Asian
population which indicated the association of TNFa -308G/A
with TB. One possible explanation for this is the genetic
similarities between Asian populations. The study by Ben-
Selma et al. [26] also indicated the association between TNFa-308G/A polymorphism and TB in the Tunisian population.
Also, study by Amirzargar et al. [27] has demonstrated the
association of TNFa -238G/A polymorphism with TB in other
ethnic group of Iranian.
TNFa is an essential cytokine in the granuloma formation.
The mice with deﬁciency in TNFa are impotent in the granu-
loma formation. This tragedy leads to MTB development and
fulminant death in the infected animals. Furthermore, the former
studies have demonstrated that TNFa blocking can lead to TB
reactivation [28,29]. Hence, despite of paradoxical ﬁndings, the
association of TNFa polymorphisms with TB seems
undeniable. However, we can indicate other TNFa
polymorphisms, the race of studied population and the size of
studied samples as the reasons of these adverse results.
Finally, our ﬁndings show that TNFa -308G/A poly-
morphism may associate with pulmonary TB in the Lur popu-
lation of Iran. Despite susceptibility to pulmonary TB, we
suggest that more studies with larger sample size should be
carried out to verify the role of TNFa polymorphisms, especially
TNFa -308G/A polymorphism in the future.
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